Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 10;2(1):vdaa004. doi: 10.1093/noajnl/vdaa004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Boxplot of mean ADC and rCBV values comparing patients with IDH-mutant gliomas who present the T2/FLAIR-mismatch sign (green color) and those who did not (blue color). Analysis of all IDH-mutant gliomas (ie, including astrocytoma, oligodendroglioma, and glioblastoma cases—top row) and separate analysis for the subset of patients with IDH-mutant astrocytomas (bottom row) were performed. The median ADC values were significantly higher in both IDH-mutant gliomas (P < .0001) and in the subset of IDH-mutant astrocytomas (P < .0001) without the T2/FLAIR-mismatch sign as compared those with a T2/FLAIR-mismatch sign (left column). The median rBCV values were significantly lower in IDH-mutant gliomas (P = .0123) with the presence of a T2/FLAIR-mismatch sign, whereas only borderline significance was found within the subset of IDH-mutant astrocytomas (P = .0757) (right column).